Eli Lilly & Co.’s full-year earnings forecast came in line with analysts’ estimates as the company works to fix inventory ...
34m
Booming sales of its blockbuster incretin-based weight loss and diabetes drugs Mounjaro and Zepbound powered Eli Lilly (LLY) to a 45% jump in ...
The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback